- Conditions
- Bacterial Vaginosis
- Interventions
- Low dose LACTIN-V applicator, Medium dose LACTIN-V applicator, High dose LACTIN-V applicator, Low dose Placebo applicator, Medium dose Placebo, High dose Placebo applicator
- Biological · Other
- Lead sponsor
- Osel, Inc.
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Papulopustular Rosacea
- Interventions
- omiganan, placebo
- Drug
- Lead sponsor
- Maruho Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Santa Monica, California • New Haven, Connecticut + 14 more
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- DE-104 medium concentration, DE-104 high concentration, Placebo, 0.005% latanoprost
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Artesia, California • Pasadena, California • San Francisco, California + 3 more
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration, Placebo, 0.005% latanoprost
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 14
- States / cities
- Artesia, California • Los Angeles, California • Torrance, California + 9 more
- Conditions
- Pediculosis
- Interventions
- Group A - Low-Dose Ha44 0.37% w/w, Group B - High Dose Ha44 Gel 0.74% w/w, Group C - Placebo
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Dinuba, California • Los Angeles, California
- Conditions
- Rhinitis, Sinusitis
- Interventions
- Quinine Sulfate, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pmm2-CDG, Phosphomannomutase 2 Deficiency, Phosphomannomutase 2 Congenital Disorder of Glycosylation, Phosphomannomutase II Congenital Disorder of Glycosylation, Phosphomannomutase II Deficiency
- Interventions
- Epalrestat, Placebo
- Drug
- Lead sponsor
- Maggie's Pearl, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hypertension
- Interventions
- Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
- Drug · Dietary Supplement · Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
- Interventions
- Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Years to 25 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
- Conditions
- Genital Warts
- Interventions
- GS-9191 ointment, GS-9191, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Beverly Hills, California • Mission Viejo, California + 20 more